You cannot register for this webinar
This webinar has ended. Thank you for your interest.
Topic
Alterity Therapeutics - Shareholder Webinar
Date & Time
Selected Sessions:
Jan 30, 2025 11:00 AM
Description
Alterity Therapeutics' CEO Dr David Stamler will be joined by Dr Daniel Claassen, Professor of Neurology at Vanderbilt University Medical Center and Coordinating Investigator for the ATH434-201 Phase 2 study, to discuss the trial results released this morning.